Tag Archive for: immunotherapy

The blockbuster immunotherapy secured separate late-stage victories as an adjuvant-setting treatment in renal cell carcinoma and muscle-invasive urothelial carcinoma.

The bladder cancer-focused company’s larger-than-expected Nasdaq debut on Thursday opens this year’s batch of planned initial public offerings, which include at least half a dozen biotechs.

Saturday’s readout, which were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, could position BMS to challenge Merck’s dominant PD-1 blocker Keytruda.

The U.S. drugmaker has been doubling down on building future revenue streams as its blockbuster immunotherapy, Keytruda, inches closer to losing key patents, opening the doors for competition from biosimilars.

BioVaxys Technology Corp. announced that it has executed a non-binding Letter of Intent to acquire the core platform technology and entire immunotherapeutics intellectual property portfolio formerly owned by an unnamed biotechnology company and now held by the unnamed company’s former secured creditor.

MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink’s ADC assets, and BioNTech will provide MediLink with an upfront payment totaling of $70 million and additional development, regulatory and commercial milestone payments potentially totaling over $1 billion.

September 24 is World Cancer Research Day, dedicated to supporting the research and innovations that improve outcomes for cancer patients across the globe. So far this year, the FDA has approved ten novel anticancer therapies, for breast cancer, multiple myeloma, acute myeloid leukemia and more. 

The pairing of Merck’s blockbuster immunotherapy Keytruda and Eisai’s Lenvima has previously failed in studies evaluating it in patients with types of head-and-neck cancer, skin cancer and colon cancer as well.

Novocure said today that its therapy failed in a late-stage trial to meet the main goal of improving survival rates in patients with a type of ovarian cancer.

Roche inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker’s shares even though more data will be needed to confirm the treatment’s efficacy.